Early Treatment / Prevention
Features
Reduces progression rates to severe COVID-19 in mild-to-moderate patients
Decreases hospitalization rate ($73,300 cost) and oxygen therapy use ($550,000 cost)
Shortens the time to clinical recovery
Molecule: Recombinant human IgG1 lambda antibody directed against SARS-CoV-2 receptor binding domain (RBD)
Authorized use: mild to moderate COVID-19 in adults with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progressing to severe COVID-19 and/or hospitalization.
Vial & dosage: 960mg per 24kg
Approvals: EMA (European Medicines Agency), FDA EUA (pending) Korea EUR (approved)
MOQ: 10,000 vials (960mg, 16ml)
FOB Korea: €650 (commission included)
MSRP: €960~€1,920
Lead time: 60~90 days
Production capacity: 200,000 vials per month
Signup today to claim your Discount. Get Started before it's too late!
